Zacks Research Has Bullish Estimate for Omnicell Q1 Earnings

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Equities research analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Omnicell in a note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.16. The consensus estimate for Omnicell's current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell's Q3 2025 earnings at $0.18 EPS, FY2025 earnings at $0.86 EPS and Q1 2026 earnings at $0.27 EPS.

Several other analysts have also recently commented on the company. Craig Hallum upped their target price on Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company reduced their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Finally, Bank of America lowered their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $50.00.

Omnicell Stock Performance

Shares of OMCL stock traded down $1.57 on Thursday, hitting $43.42. The company had a trading volume of 351,821 shares, compared to its average volume of 322,306. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74. The firm has a market cap of $2.01 billion, a P/E ratio of -111.33, a P/E/G ratio of 30.78 and a beta of 0.78. The stock's 50-day moving average is $44.69 and its two-hundred day moving average is $42.99.

Institutional Investors Weigh In On Omnicell

Hedge funds and other institutional investors have recently modified their holdings of the company. Van ECK Associates Corp grew its position in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the period. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after buying an additional 553 shares in the last quarter. Curi RMB Capital LLC grew its holdings in shares of Omnicell by 0.7% during the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company's stock valued at $3,872,000 after buying an additional 651 shares during the last quarter. KBC Group NV increased its position in shares of Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company's stock worth $92,000 after acquiring an additional 778 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Omnicell by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company's stock worth $635,000 after acquiring an additional 1,360 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company's stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.64% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.